nefazodone and Aging studies

Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.

Research Excerpts

Excerpt	Relevance	Reference
" One hundred fifteen female outpatients who met DSM-IV criteria for major depressive disorder were evaluated before and after 8 weeks of treatment with a selective serotonin reuptake inhibitor, nefazodone, or venlafaxine."	5.10	A comparison of antidepressant response in younger and older women. ( Bagby, RM; Grigoriadis, S; Kennedy, SH, 2003)
"Nefazodone was efficacious in symptom alleviation in patients with comorbid anxiety and depression."	2.71	Mixed anxiety and depression in older adults: clinical characteristics and management. ( Cassidy, EL; Lauderdale, S; Sheikh, JI, 2005)
" Serial blood samples were collected after the single dose and the morning dose on day 8 of the twice-daily administration; a blood sample for trough level was collected from each subject just before the morning dose on days 2 to 8 of the twice-daily dosing to assess the attainment of steady state."	2.68	A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. ( Barbhaiya, RH; Buch, AB; Greene, DS, 1996)
"Moclobemide is a selective inhibitor of monoamine oxidase type A."	2.40	Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide. ( Goldberg, RJ, 1997)

Research

Studies (6)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Change in Frontostriatal Reactivity to Reward During MID fMRI Task

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (50.00)	18.2507
2000's	3 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Núñez, MJ	1
Rivas, M	1
Riveiro, P	1
Suárez, J	1
Balboa, J	1
Núñez, LA	1
Rey-Méndez, M	1
Freire-Garabal, M	1
Grigoriadis, S	1
Kennedy, SH	1
Bagby, RM	1
Cassidy, EL	1
Lauderdale, S	1
Sheikh, JI	1
van Laar, MW	1
van Willigenburg, AP	1
Volkerts, ER	1
Barbhaiya, RH	1
Buch, AB	1
Greene, DS	1
Goldberg, RJ	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Effect of the Menstrual Cycle on the Symptoms of Depression and Treatment Response: A Comparison of Premenopausal, Perimenopausal and Postmenopausal Women[NCT00188396]		44 participants (Actual)	Interventional	2004-04-30	Completed
Effects of a Tissue Selective Estrogen Complex (TESC) on Depression and the Neural Reward System in the Perimenopause[NCT03740009]	Phase 4	20 participants (Actual)	Interventional	2019-01-02	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"The primary outcome measure is functional magnetic resonance imaging (fMRI) data collected during a Monetary Incentive Delay (MID) Task. All participants will complete the fMRI Monetary Incentive Delay (MID) task at baseline and at 3 weeks. During the task, participants need to select the correct response during win and lose conditions by pressing a button on a button box in the MRI. Participant's blood-oxygen-level dependent (BOLD) activation response (A measurement of oxygen level that is released to neurons since areas of the brain that are thought to be more active or involved in certain tasks require more oxygen to perform the tasks.) is measured while they performed the task in MRI scanner." (NCT03740009)
Timeframe: Baseline to 3 weeks

Depressive Symptoms as Measured by the MASQ-AD

Intervention	percent signal change (Mean)
	Caudate Baseline	Caudate Posttreatment	Nucleus Accumbens Baseline	Nucleus Accumbens Posttreatment	Putamen Baseline	Putamen Posttreatment
Perimenopausal Women, Depressed	.0704	.0475	.0623	.0280	.0399	.0408

The second primary outcome measure uses the Mood and Anxiety Symptoms Questionnaire - Anhedonic Depression Scale (MASQ-AD) to examine symptom change. All participants will complete the MASQ-AD at each study visit, which measures their current symptoms of depression and anxiety. Scores range from 22 to 110 with lower scores reflecting a better outcome. (NCT03740009)
Timeframe: Baseline, week 2, week 3, week 4 (post treatment)

Intervention	score on a scale (Mean)
	Baseline Week 1	Week 2	Week 3	Post Treatment Week 4
Perimenopausal Women, Depressed	72.1	62.4	57.2	54.5

Article	Year
A comparison of antidepressant response in younger and older women. Journal of clinical psychopharmacology, 2003, Volume: 23, Issue:4 Topics: Adult; Aged; Aging; Antidepressive Agents; Antidepressive Agents, Second-Generation; Depressive Diso	2003
A comparison of antidepressant response in younger and older women. Journal of clinical psychopharmacology, 2003, Volume: 23, Issue:4 Topics: Adult; Aged; Aging; Antidepressive Agents; Antidepressive Agents, Second-Generation; Depressive Diso	2003
A comparison of antidepressant response in younger and older women. Journal of clinical psychopharmacology, 2003, Volume: 23, Issue:4 Topics: Adult; Aged; Aging; Antidepressive Agents; Antidepressive Agents, Second-Generation; Depressive Diso	2003
A comparison of antidepressant response in younger and older women. Journal of clinical psychopharmacology, 2003, Volume: 23, Issue:4 Topics: Adult; Aged; Aging; Antidepressive Agents; Antidepressive Agents, Second-Generation; Depressive Diso	2003
Mixed anxiety and depression in older adults: clinical characteristics and management. Journal of geriatric psychiatry and neurology, 2005, Volume: 18, Issue:2 Topics: Aged; Aging; Antidepressive Agents, Second-Generation; Anxiety Disorders; Comorbidity; Depressive Di	2005
Acute and subchronic effects of nefazodone and imipramine on highway driving, cognitive functions, and daytime sleepiness in healthy adult and elderly subjects. Journal of clinical psychopharmacology, 1995, Volume: 15, Issue:1 Topics: Adult; Aged; Aging; Antidepressive Agents; Automobile Driving; Cognition; Double-Blind Method; Human	1995
A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. Journal of clinical psychopharmacology, 1996, Volume: 16, Issue:1 Topics: Adolescent; Adult; Aged; Aging; Antidepressive Agents, Second-Generation; Biotransformation; Female;	1996

nefazodone and Aging